Loading...
OTCM
MDXXF
Market cap6mUSD
Jun 10, Last price  
0.08USD
Name

Pharmala Biotech Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
8.60
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
1m
+94.60%
078,070532,0031,035,297
Net income
-824k
L+5.61%
-2,509,066-985,583-779,813-823,596
CFO
-321k
L-5.39%
-173,573-625,371-339,656-321,360

Profile

Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
IPO date
Jan 11, 2022
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFY
2024‑082023‑082022‑082021‑08
Income
Revenues
1,035
94.60%
532
581.44%
78
 
Cost of revenue
1,473
1,063
1,052
Unusual Expense (Income)
NOPBT
(438)
(531)
(973)
NOPBT Margin
Operating Taxes
(3)
Tax Rate
NOPAT
(438)
(531)
(973)
Net income
(824)
5.61%
(780)
-20.88%
(986)
-60.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
697
189
BB yield
Debt
Debt current
254
(372)
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(419)
58
(1,224)
Cash flow
Cash from operating activities
(321)
(340)
(625)
CAPEX
(226)
(995)
Cash from investing activities
(226)
(507)
(995)
Cash from financing activities
772
189
FCF
(498)
(468)
(975)
Balance
Cash
419
195
852
Long term investments
Excess cash
368
168
848
Stockholders' equity
739
1,007
1,527
Invested Capital
1,614
1,469
686
ROIC
ROCE
EV
Common stock shares outstanding
88,574
84,527
82,999
Price
Market cap
EV
EBITDA
(367)
(479)
(961)
EV/EBITDA
Interest
Interest/NOPBT